RealTime Dynamix™: Hyperkalemia US Q1 2018 Spotlight

hyperkalemia q1

A survey of 99 nephrologists provides a detailed and timely look at how the hyperkalemia market is evolving with quarterly updates of hyperkalemia treatment patterns, comparative industry contact rates, key launch metrics for Veltassa (and later Lokelma) and awareness of products in development. See complimentary highlights from the Q1 2018 wave of RealTime Dynamix™: Hyperkalemia (Nephrology Perspective) US below.

Contact [email protected] for more information about the highlighted report or to see if your company already has access to the report series.

All company, brand or product names and logos in this document are trademarks of their respective holders.